Intranasal immunization with outer membrane vesicle pertussis vaccine confers broad protection through mucosal IgA and Th17 responses.
Administration, Intranasal
Animals
Antibodies, Bacterial
/ immunology
B-Lymphocytes
/ immunology
Bordetella pertussis
/ immunology
Cell-Derived Microparticles
/ immunology
Female
Immunity, Mucosal
Immunoglobulin A
/ immunology
Immunologic Memory
Mice
Mice, Inbred BALB C
Pertussis Vaccine
/ immunology
Th1 Cells
/ immunology
Th17 Cells
/ immunology
Whooping Cough
/ immunology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 04 2020
30 04 2020
Historique:
received:
10
01
2020
accepted:
08
04
2020
entrez:
2
5
2020
pubmed:
2
5
2020
medline:
1
12
2020
Statut:
epublish
Résumé
A vaccine based on outer membrane vesicles of pertussis (omvPV) is protective in a mouse-challenge model and induces a broad antibody and mixed Th1/Th2/Th17 response against multiple antigens following subcutaneous immunization. However, this route did not result in mucosal immunity and did not prevent nasopharyngeal colonization. In this study, we explored the potential of intranasal immunization with omvPV. Only intranasal immunization induced strong mucosal immune responses that encompasses enhanced pulmonary and nasal IgA antibody levels, mainly directed against Vag8 and LPS. Furthermore, high numbers of IgA- and IgG-producing plasma cells were detected as well as lung-resident IgA memory B-cells. Finally, only intranasal immunization induced pulmonary Th1/Th17-related cytokine responses. The magnitude and type of systemic immunity was comparable between both routes and included high systemic IgG antibody levels, strong IgG-producing plasma cell responses, memory B-cells residing in the spleen and systemic Th1/Th2/Th17-related cytokine responses. Importantly, only intranasal immunization prevented colonization in both the lungs and the nasal cavity. In conclusion, intranasal omvPV immunization induces mucosal IgA and Th17-mediated responses without influencing the systemic immunity profile. These responses resulted in prevention of Bordetella pertussis colonization in the respiratory tract, including the nasal cavity, thereby potentially preventing transmission.
Identifiants
pubmed: 32355188
doi: 10.1038/s41598-020-63998-2
pii: 10.1038/s41598-020-63998-2
pmc: PMC7192948
doi:
Substances chimiques
Antibodies, Bacterial
0
Immunoglobulin A
0
Pertussis Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7396Références
Pertussis vaccines: WHO position paper. Releve epidemiologique hebdomadaire / Section d’hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations 85, 385–400 (2010).
Libster, R. & Edwards, K. M. Re-emergence of pertussis: what are the solutions? Expert review of vaccines 11, 1331–1346, https://doi.org/10.1586/erv.12.118 (2012).
doi: 10.1586/erv.12.118
pubmed: 23249233
Martinon-Torres, F., Heininger, U., Thomson, A. & Wirsing von Konig, C. H. Controlling pertussis: how can we do it? A focus on immunization. Expert review of vaccines 17, 289–297, https://doi.org/10.1080/14760584.2018.1445530 (2018).
doi: 10.1080/14760584.2018.1445530
pubmed: 29482390
Burdin, N., Handy, L. K. & Plotkin, S. A. What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines. Cold Spring Harb Perspect Biol 9, https://doi.org/10.1101/cshperspect.a029454 (2017).
Warfel, J. M., Zimmerman, L. I. & Merkel, T. J. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proceedings of the National Academy of Sciences of the United States of America 111, 787–792, https://doi.org/10.1073/pnas.1314688110 (2014).
doi: 10.1073/pnas.1314688110
pubmed: 24277828
Gill, C., Rohani, P. & Thea, D. M. The relationship between mucosal immunity, nasopharyngeal carriage, asymptomatic transmission and the resurgence of Bordetella pertussis. F1000Res 6, 1568, https://doi.org/10.12688/f1000research.11654.1 (2017).
doi: 10.12688/f1000research.11654.1
pubmed: 28928960
pmcid: 5580413
Solans, L. & Locht, C. The Role of Mucosal Immunity in Pertussis. Frontiers in immunology 9, 3068, https://doi.org/10.3389/fimmu.2018.03068 (2018).
doi: 10.3389/fimmu.2018.03068
pubmed: 30692990
Warfel, J. M. & Merkel, T. J. Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal immunology 6, 787–796, https://doi.org/10.1038/mi.2012.117 (2013).
doi: 10.1038/mi.2012.117
pubmed: 23187316
Raeven, R. H. M. et al. Molecular Signatures of the Evolving Immune Response in Mice following a Bordetella pertussis Infection. PloS one 9, e104548, https://doi.org/10.1371/journal.pone.0104548 (2014).
doi: 10.1371/journal.pone.0104548
pubmed: 25137043
pmcid: 4138111
Solans, L. et al. IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1. vaccine. Mucosal immunology 11, 1753–1762, https://doi.org/10.1038/s41385-018-0073-9 (2018).
doi: 10.1038/s41385-018-0073-9
pubmed: 30115992
Hozbor, D. F. Outer membrane vesicles: an attractive candidate for pertussis vaccines. Expert review of vaccines 16, 193–196, https://doi.org/10.1080/14760584.2017.1276832 (2017).
doi: 10.1080/14760584.2017.1276832
pubmed: 28010142
Roberts, R. et al. Outer membrane vesicles as acellular vaccine against pertussis. Vaccine 26, 4639–4646, https://doi.org/10.1016/j.vaccine.2008.07.004 (2008).
doi: 10.1016/j.vaccine.2008.07.004
pubmed: 18640169
Raeven, R. H. M. et al. Bordetella pertussis outer membrane vesicle vaccine confers equal efficacy in mice with milder inflammatory responses compared to a whole-cell vaccine. Sci Rep 6, 38240, https://doi.org/10.1038/srep38240 (2016).
doi: 10.1038/srep38240
pubmed: 27905535
pmcid: 5131296
Bottero, D. et al. Characterization of the immune response induced by pertussis OMVs-based vaccine. Vaccine 34, 3303–3309, https://doi.org/10.1016/j.vaccine.2016.04.079 (2016).
doi: 10.1016/j.vaccine.2016.04.079
pubmed: 27151884
Raeven, R. H. M. et al. Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination. Mucosal immunology 11, 979–993, https://doi.org/10.1038/mi.2017.81 (2018).
doi: 10.1038/mi.2017.81
pubmed: 28930286
Raeven, R. H. M. et al. Immunoproteomic Profiling of Bordetella pertussis Outer Membrane Vesicle Vaccine Reveals Broad and Balanced Humoral Immunogenicity. Journal of proteome research 14, 2929–2942, https://doi.org/10.1021/acs.jproteome.5b00258 (2015).
doi: 10.1021/acs.jproteome.5b00258
pubmed: 25988566
Kubler-Kielb, J. et al. Oligosaccharide conjugates of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition to pertussis vaccine. Proceedings of the National Academy of Sciences of the United States of America 108, 4087–4092, https://doi.org/10.1073/pnas.1100782108 (2011).
doi: 10.1073/pnas.1100782108
pubmed: 21367691
pmcid: 3054038
Suzuki, K. et al. Protective effects of in vivo-expressed autotransporters against Bordetella pertussis infection. Microbiol Immunol 61, 371–379, https://doi.org/10.1111/1348-0421.12504 (2017).
doi: 10.1111/1348-0421.12504
pubmed: 28752940
Weiss, A. A., Mobberley, P. S., Fernandez, R. C. & Mink, C. M. Characterization of human bactericidal antibodies to Bordetella pertussis. Infection and immunity 67, 1424–1431 (1999).
doi: 10.1128/IAI.67.3.1424-1431.1999
Marr, N. et al. Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model. Vaccine 26, 4306–4311, https://doi.org/10.1016/j.vaccine.2008.06.017 (2008).
doi: 10.1016/j.vaccine.2008.06.017
pubmed: 18582518
Kanojia, G. et al. Development of a thermostable spray dried outer membrane vesicle pertussis vaccine for pulmonary immunization. J Control Release 286, 167–178, https://doi.org/10.1016/j.jconrel.2018.07.035 (2018).
Jabbal-Gill, I. Nasal vaccine innovation. J. Drug Target. 18, 771–786, https://doi.org/10.3109/1061186X.2010.523790 (2010).
doi: 10.3109/1061186X.2010.523790
pubmed: 21047271
Thalen, M. et al. Rational medium design for Bordetella pertussis: basic metabolism. Journal of biotechnology 75, 147–159 (1999).
doi: 10.1016/S0168-1656(99)00155-8
Crotty, S., Aubert, R. D., Glidewell, J. & Ahmed, R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J. Immunol Methods. 286, 111–122, https://doi.org/10.1016/j.jim.2003.12.015 (2004).
doi: 10.1016/j.jim.2003.12.015
pubmed: 15087226
Brummelman, J., Wilk, M. M., Han, W. G., van Els, C. A. & Mills, K. H. Roads to the development of improved pertussis vaccines paved by immunology. Pathogens and disease 73, ftv067, https://doi.org/10.1093/femspd/ftv067 (2015).
doi: 10.1093/femspd/ftv067
pubmed: 26347400
pmcid: 4626578
Lam, C. et al. Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia. Emerging infectious diseases 20, 626–633, https://doi.org/10.3201/eid2004.131478 (2014).
doi: 10.3201/eid2004.131478
pubmed: 24655754
pmcid: 3966384
Etskovitz, H., Anastasio, N., Green, E. & May, M. Role of Evolutionary Selection Acting on Vaccine Antigens in the Re-Emergence of Bordetella Pertussis. Diseases 7, https://doi.org/10.3390/diseases7020035 (2019).
Oliver, D. C. & Fernandez, R. C. Antibodies to BrkA augment killing of Bordetella pertussis. Vaccine 20, 235–241 (2001).
doi: 10.1016/S0264-410X(01)00269-9
Hovingh, E. S. et al. Detection of opsonizing antibodies directed against a recently circulating Bordetella pertussis strain in paired plasma samples from symptomatic and recovered pertussis patients. Sci. Rep. 8, 12039, https://doi.org/10.1038/s41598-018-30558-8 (2018).
doi: 10.1038/s41598-018-30558-8
pubmed: 30104573
pmcid: 6089961
Raeven, R. H. M. et al. Antibody Specificity Following a Recent Bordetella pertussis Infection in Adolescence Is Correlated With the Pertussis Vaccine Received in Childhood. Frontiers in immunology 10, 1364, https://doi.org/10.3389/fimmu.2019.01364 (2019).
doi: 10.3389/fimmu.2019.01364
pubmed: 31275314
pmcid: 6592373
Tuomanen, E. I., Zapiain, L. A., Galvan, P. & Hewlett, E. L. Characterization of antibody inhibiting adherence of Bordetella pertussis to human respiratory epithelial cells. Journal of clinical microbiology 20, 167–170 (1984).
doi: 10.1128/JCM.20.2.167-170.1984
Geurtsen, J., Fae, K. C. & van den Dobbelsteen, G. P. Importance of (antibody-dependent) complement-mediated serum killing in protection against Bordetella pertussis. Expert review of vaccines 10, 1229–40, https://doi.org/10.1586/14760584.2014.944901 (2014).
Holmgren, J. & Czerkinsky, C. Mucosal immunity and vaccines. Nature medicine 11, S45–53, https://doi.org/10.1038/nm1213 (2005).
doi: 10.1038/nm1213
pubmed: 15812489
Mueller, S. N. & Mackay, L. K. Tissue-resident memory T cells: local specialists in immune defence. Nature reviews. Immunology 16, 79–89, https://doi.org/10.1038/nri.2015.3 (2016).
doi: 10.1038/nri.2015.3
pubmed: 26688350
Chiu, C. & Openshaw, P. J. Antiviral B cell and T cell immunity in the lungs. Nature immunology 16, 18–26, https://doi.org/10.1038/ni.3056 (2015).
doi: 10.1038/ni.3056
pubmed: 25521681
Park, C. O. & Kupper, T. S. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nature medicine 21, 688–697, https://doi.org/10.1038/nm.3883 (2015).
doi: 10.1038/nm.3883
pubmed: 26121195
pmcid: 4640452
Mielcarek, N. et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. Plos pathogens 2, e65, https://doi.org/10.1371/journal.ppat.0020065 (2006).
doi: 10.1371/journal.ppat.0020065
pubmed: 16839199
pmcid: 1487175
Shi, W. et al. Novel intranasal pertussis vaccine based on bacterium-like particles as a mucosal adjuvant. Immunol Lett 198, 26–32, https://doi.org/10.1016/j.imlet.2018.03.012 (2018).
doi: 10.1016/j.imlet.2018.03.012
pubmed: 29601940
Asokanathan, C., Corbel, M. & Xing, D. A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis. Human vaccines & immunotherapeutics 9, 325–331 (2013).
doi: 10.4161/hv.22755
Allen, A. C. et al. Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM. cells. Mucosal immunology 11, 1763–1776, https://doi.org/10.1038/s41385-018-0080-x (2018).
doi: 10.1038/s41385-018-0080-x
pubmed: 30127384
Isaka, M. et al. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant. Vaccine 21, 1165–1173 (2003).
doi: 10.1016/S0264-410X(02)00516-9
Asensio, C. J. et al. Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate. Vaccine 29, 1649–1656, https://doi.org/10.1016/j.vaccine.2010.12.068 (2011).
doi: 10.1016/j.vaccine.2010.12.068
pubmed: 21211579
Allie, S. R. et al. The establishment of resident memory B cells in the lung requires local antigen encounter. Nature immunology 20, 97–108, https://doi.org/10.1038/s41590-018-0260-6 (2019).
doi: 10.1038/s41590-018-0260-6
pubmed: 30510223
Hellwig, S. M., van Spriel, A. B., Schellekens, J. F., Mooi, F. R. & van de Winkel, J. G. Immunoglobulin A-mediated protection against Bordetella pertussis infection. Infection and immunity 69, 4846–4850, https://doi.org/10.1128/IAI.69.8.4846-4850.2001 (2001).
doi: 10.1128/IAI.69.8.4846-4850.2001
pubmed: 11447159
pmcid: 98573
Ross, P. J. et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. Plos pathogens 9, e1003264, https://doi.org/10.1371/journal.ppat.1003264 (2013).
doi: 10.1371/journal.ppat.1003264
pubmed: 23592988
pmcid: 3617212
Raeven, R. H. M. et al. Immunological Signatures after Bordetella pertussis Infection Demonstrate Importance of Pulmonary Innate Immune Cells. Plos one 11, e0164027, https://doi.org/10.1371/journal.pone.0164027 (2016).
doi: 10.1371/journal.pone.0164027
pubmed: 27711188
pmcid: 5053408
Wilk, M. M. et al. Lung CD4 Tissue-Resident Memory T Cells Mediate Adaptive Immunity Induced by Previous Infection of Mice with Bordetella pertussis. J. Immunol. 199, 233–243, https://doi.org/10.4049/jimmunol.1602051 (2017).
doi: 10.4049/jimmunol.1602051
pubmed: 28533445
Zariri, A. & van der Ley, P. Biosynthetically engineered lipopolysaccharide as vaccine adjuvant. Expert review of vaccines 14, 861–876, https://doi.org/10.1586/14760584.2015.1026808 (2015).
doi: 10.1586/14760584.2015.1026808
pubmed: 25797360
Launay, O. et al. Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe. EBioMedicine 22, 164–172, https://doi.org/10.1016/j.ebiom.2017.07.013 (2017).
doi: 10.1016/j.ebiom.2017.07.013
pubmed: 28735965
pmcid: 5552227
Fries, L. F. et al. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infection and immunity 69, 4545–4553, https://doi.org/10.1128/IAI.69.7.4545-4553.2001 (2001).
doi: 10.1128/IAI.69.7.4545-4553.2001
pubmed: 11401998
pmcid: 98531
Lewis, D. J. et al. Transient facial nerve paralysis (Bell’s palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. Plos one 4, e6999, https://doi.org/10.1371/journal.pone.0006999 (2009).
doi: 10.1371/journal.pone.0006999
pubmed: 19756141
pmcid: 2737308
Valli, E. et al. LTA1 is a safe, intranasal enterotoxin-based adjuvant that improves vaccine protection against influenza in young, old and B-cell-depleted (muMT) mice. Sci. Rep. 9, 15128, https://doi.org/10.1038/s41598-019-51356-w (2019).
doi: 10.1038/s41598-019-51356-w
pubmed: 31641151
pmcid: 6805908
Birkhoff, M., Leitz, M. & Marx, D. Advantages of Intranasal Vaccination and Considerations on Device Selection. Indian Journal of Pharmaceutical Sciences 71, 729–731 (2009).
pmcid: 2846493
Merkel, T. J. & Halperin, S. A. Nonhuman primate and human challenge models of pertussis. The Journal of infectious diseases 209(Suppl 1), S20–23, https://doi.org/10.1093/infdis/jit493 (2014).
doi: 10.1093/infdis/jit493
pubmed: 24626867
pmcid: 4048992
Wendelboe, A. M. et al. Transmission of Bordetella pertussis to young infants. The Pediatric infectious disease journal 26, 293–299, https://doi.org/10.1097/01.inf.0000258699.64164.6d (2007).
doi: 10.1097/01.inf.0000258699.64164.6d
pubmed: 17414390
da Silva Antunes, R. et al. Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters. The Journal of clinical investigation 128, 3853–3865, https://doi.org/10.1172/JCI121309 (2018).
doi: 10.1172/JCI121309
pubmed: 29920186
pmcid: 6118631